← Leaderboards
Maria Agostini
Vanderbilt University
$62,851
Attributed
$62,851
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $29.2K · FY2017–19$50K$37.5K$25K$12.5K$0
'17
'18
'19
Funding mix
By agency
NIH$62,851 · 1
By mechanism
F31$62,851 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Mark R Denison$28,746,770
- Eugene M. Oltz$20,457,685
- Kevin Whittle Graepel$113,263
- Ardina Jannetje Pruijssers$159,186
- Helen Keipp Talbot$7,247,906
Others in their field
Other Emerging Leaders on “Adenosine”
- Danielle L Swaney · University Of California, San Francisco$4,769,065
- Theodore E Liston · Astrocyte Pharmaceuticals, Inc.$4,495,704
- Wei Lu · Van Andel Research Institute$4,058,147
- Bing Yao · Emory University$3,941,624
- Kim-Lien T Nguyen · Va Greater Los Angeles Healthcare System$3,836,883
- Rebecca Diane Levit · Emory University$3,716,694
Research focus
Adenosine5&AposAntiviral AgentsAntiviral Nucleoside AnalogAntiviral TherapyAffectClinical DevelopmentClinically RelevantCollaborationsCombatCommon ColdComplexBlood CirculationCoronavirusCoronavirus InfectionsCytotoxicityDeep SequencingDefective VirusesDrug DevelopmentDrug DiscoveryExcisionExons-ExoribonucleaseExoribonucleases
Grant awards (3)
Coronavirus antiviral nucleoside analogs: inhibition and reduced susceptibility$4,919
F31 · FY2019 · AI · contact PI
Coronavirus antiviral nucleoside analogs: inhibition and reduced susceptibility$29,206
F31 · FY2018 · AI · contact PI
Coronavirus antiviral nucleoside analogs: inhibition and reduced susceptibility$28,726
F31 · FY2017 · AI · contact PI